EA200001186A1 - THERAPEUTIC COMBINATION (ELECTIONAL) MODULATORS OF ESTROGEN RECEPTORS (IMRE) AND GROWTH HORMONE SECRETION STIMULATORS (SSGR) FOR THE TREATMENT OF MUSCULAR MUSCLE - Google Patents

THERAPEUTIC COMBINATION (ELECTIONAL) MODULATORS OF ESTROGEN RECEPTORS (IMRE) AND GROWTH HORMONE SECRETION STIMULATORS (SSGR) FOR THE TREATMENT OF MUSCULAR MUSCLE

Info

Publication number
EA200001186A1
EA200001186A1 EA200001186A EA200001186A EA200001186A1 EA 200001186 A1 EA200001186 A1 EA 200001186A1 EA 200001186 A EA200001186 A EA 200001186A EA 200001186 A EA200001186 A EA 200001186A EA 200001186 A1 EA200001186 A1 EA 200001186A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
electional
ssgr
imre
modulators
Prior art date
Application number
EA200001186A
Other languages
Russian (ru)
Inventor
Хуа Жу Ки
Мей ЛИ
Лидия Кодетта Пэн
Дейвид Дуйэн Томпсон
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200001186A1 publication Critical patent/EA200001186A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Данное изобретение относится к композициям фармацевтических комбинаций и способам, содержащим (-)-цис-6-фенил-5-(4-(2-пирролидин-1-ил-этокси)-фенил)-5,6,7,8-тетрагидронафталин-2-ол или его фармацевтически приемлемую соль и 2-амино-N-(2-(3a(R)-бензил-2-метил-3-оксо-2,3,3a,4,6,7-гексагидропиразоло-[4,3-c]пиридин-5-ил)-1(R)-бензилоксиметил-2-оксо-этил)-изобутирамид или его фармацевтически приемлемую соль, способам применения таких композиций и наборам, содержащим такие композиции. Эти композиции полезны для лечения скелетно-мышечной слабости, включая остеопороз, остеопорозный перелом, низкую костную массу, слабость и низкую мышечную массу.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to compositions of pharmaceutical combinations and methods comprising (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7,8-tetrahydronaphthalene -2-ol or its pharmaceutically acceptable salt and 2-amino-N- (2- (3a (R) -benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydropyrazolo- [ 4,3-c] pyridin-5-yl) -1 (R) -benzyloxymethyl-2-oxo-ethyl) -isobutyramide or its pharmaceutically acceptable salt, methods of using such compositions, and kits containing such compositions. These compositions are useful for treating musculoskeletal weakness, including osteoporosis, osteoporotic fracture, low bone mass, weakness, and low muscle mass. The international application was published along with an international search report.

EA200001186A 1998-06-16 1999-06-16 THERAPEUTIC COMBINATION (ELECTIONAL) MODULATORS OF ESTROGEN RECEPTORS (IMRE) AND GROWTH HORMONE SECRETION STIMULATORS (SSGR) FOR THE TREATMENT OF MUSCULAR MUSCLE EA200001186A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16
PCT/IB1999/001117 WO1999065486A1 (en) 1998-06-16 1999-06-16 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
EA200001186A1 true EA200001186A1 (en) 2001-06-25

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001186A EA200001186A1 (en) 1998-06-16 1999-06-16 THERAPEUTIC COMBINATION (ELECTIONAL) MODULATORS OF ESTROGEN RECEPTORS (IMRE) AND GROWTH HORMONE SECRETION STIMULATORS (SSGR) FOR THE TREATMENT OF MUSCULAR MUSCLE

Country Status (30)

Country Link
EP (1) EP1087764A1 (en)
JP (1) JP2002518326A (en)
KR (1) KR20010052852A (en)
CN (1) CN1301160A (en)
AP (1) AP9901582A0 (en)
AR (1) AR018869A1 (en)
AU (1) AU4054799A (en)
BG (1) BG105041A (en)
BR (1) BR9911324A (en)
CA (1) CA2335134A1 (en)
CO (1) CO5070587A1 (en)
EA (1) EA200001186A1 (en)
GT (1) GT199900087A (en)
HN (1) HN1999000097A (en)
HR (1) HRP20000859A2 (en)
HU (1) HUP0102505A3 (en)
ID (1) ID27599A (en)
IL (1) IL138630A0 (en)
IS (1) IS5691A (en)
MA (1) MA26652A1 (en)
NO (1) NO20006312D0 (en)
OA (1) OA11505A (en)
PA (1) PA8475901A1 (en)
PE (1) PE20000646A1 (en)
PL (1) PL344981A1 (en)
SK (1) SK18912000A3 (en)
TN (1) TNSN99124A1 (en)
TR (1) TR200003544T2 (en)
WO (1) WO1999065486A1 (en)
ZA (1) ZA993975B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
DE60124616T2 (en) 2000-05-08 2007-09-13 Pfizer Products Inc., Groton Enzymatic cleavage of selective modulators of the estrogen receptor
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS

Also Published As

Publication number Publication date
HUP0102505A3 (en) 2002-12-28
AR018869A1 (en) 2001-12-12
PE20000646A1 (en) 2000-08-05
AP9901582A0 (en) 1999-06-30
PA8475901A1 (en) 2000-05-24
ID27599A (en) 2001-04-12
KR20010052852A (en) 2001-06-25
WO1999065486A1 (en) 1999-12-23
OA11505A (en) 2004-05-07
BG105041A (en) 2001-08-31
AU4054799A (en) 2000-01-05
SK18912000A3 (en) 2001-10-08
IS5691A (en) 2000-10-27
MA26652A1 (en) 2004-12-20
HUP0102505A2 (en) 2001-11-28
IL138630A0 (en) 2001-10-31
BR9911324A (en) 2001-04-03
NO20006312L (en) 2000-12-12
HN1999000097A (en) 1999-11-03
PL344981A1 (en) 2001-11-19
CA2335134A1 (en) 1999-12-23
NO20006312D0 (en) 2000-12-12
CN1301160A (en) 2001-06-27
EP1087764A1 (en) 2001-04-04
JP2002518326A (en) 2002-06-25
HRP20000859A2 (en) 2001-04-30
TNSN99124A1 (en) 2005-11-10
TR200003544T2 (en) 2001-04-20
CO5070587A1 (en) 2001-08-28
ZA993975B (en) 2000-12-15
GT199900087A (en) 2000-12-07

Similar Documents

Publication Publication Date Title
DE60037836D1 (en) ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
LU91145I2 (en) FIROCOXIB optionally in the form of a pharmaceutically acceptable salt (PREVICOX).
NO20052219L (en) Procedures for the Treatment of Post-Surgical Pain by Administration of a Nerve Growth Factor Antagonist and Preparations Containing This
NO990663D0 (en) Substituted pyrimidine derivatives and their pharmaceutical use
MY131911A (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2h-benzopyran or dihydrobenzodioxin) carboxamide derivatives
UA84146C2 (en) Amides of pyrrolopyridine-2-carboxylic acid as inhibitors of glycogen phosphorylase, method for their synthesis, drug formulation, and their use as therapeutic agents
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EA200001186A1 (en) THERAPEUTIC COMBINATION (ELECTIONAL) MODULATORS OF ESTROGEN RECEPTORS (IMRE) AND GROWTH HORMONE SECRETION STIMULATORS (SSGR) FOR THE TREATMENT OF MUSCULAR MUSCLE
EA200000785A1 (en) NEW SULPHONAMIDE DERIVATIVES AS THE BONE TISSUE ABSORPTION INHIBITORS AND CELL ADHESION INHIBITORS
AP9901580A0 (en) Therapeutic combination comprising a selective estrogen receptor modulator and parathyroid hormone.
EA200001189A1 (en) THERAPEUTIC COMBINATION (ELECTIONAL) MODULATORS OF ESTROGEN RECEPTORS (IMRE) AND GROWTH HORMONE SECRETION STIMULATORS (SSGR) FOR THE TREATMENT OF MUSCULAR MUSCLE
NZ504051A (en) Crystalline polymorphs of 1,3-di-cyclopropylmethyl-8-amino xanthine (cypamfylline), and the use of these compounds for treating PDE4 or TNF mediated diseases
DE69916932D1 (en) Combination therapeutic agents containing a selective estrogen receptor modulator and prostaglandin E2
ECSP993021A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
RU1805984C (en) Method for treatment of patients having complicated tubular bone fractures
ECSP993020A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
TH57984A3 (en) A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone.
UA40196A (en) Method for surgical treatment of dislocation-fracture of proximal end of humerus